At this point, the amount of LIST in the cell is sufficient to prevent c‐Src Tyr530 phosphorylation by inhibiting the binding of c‐Src to CHK and CSK kinases, resulting in a continuous increase in c‐Src activity, which enhances P‐gp transport activity by modulating Cav1 phosphorylation, thereby leading to drug resistance development and malignant tumor growth (Figure 9G). The gene discussed is SRC; the disease is cancer.